• Who it affects: Both men and women can develop tylosis, but certain hereditary forms are more common in males (X‑linked tylosis). Acquired hyperkeratosis is also seen in older adults, people with chronic friction or pressure on the skin, and individuals with underlying systemic diseases.
• Prevalence: Precise global prevalence data are limited because tylosis is often classified under broader “palmoplantar keratoderma” (PPK) categories. Estimates for hereditary PPK range from 1 in 30,000 to 1 in 100,000 persons worldwide (Mayo Clinic, 2022). Acquired hyperkeratosis associated with conditions such as psoriasis or eczema is far more common, affecting up to 3% of the adult population.
• Age of onset: Hereditary forms typically appear in childhood or early adolescence, whereas acquired hyperkeratosis usually develops in adulthood after prolonged exposure to irritants, friction, or systemic disease.

Symptoms

Symptoms vary by type (hereditary vs. acquired) and body location, but the following list covers the most frequent presentations.

Cutaneous signs

• Thickened plaques – Well‑defined, raised, leathery areas on the palms and soles; can also appear on knuckles, elbows, knees, or scalp.
• Callus‑like lesions – Rough, yellow‑white, or hyperpigmented spots that may be painful when pressure is applied.
• Scaling or flaking – The thickened skin may shed in small sheets, especially after soaking or sweating.
• Redness (erythema) – In inflamed lesions, the surrounding skin can become red and tender.
• Cracking or fissuring – Deep lines may develop, increasing the risk of infection.

Functional complaints

• Pain or burning sensation – Particularly when walking, gripping, or performing manual tasks.
• Decreased sensation – In severe cases, thickened skin can compress nerve endings, leading to numbness.
• Difficulty with footwear – Shoes may feel tight; patients may need custom orthotics.

Systemic associations (when hyperkeratosis is a manifestation of another disease)

• Itching (pruritus) linked to eczema‑associated hyperkeratosis.
• Joint pain or stiffness if associated with psoriatic arthritis.
• Gastrointestinal symptoms in rare syndromes such as tylosis‑esophageal cancer syndrome.

Causes and Risk Factors

Hereditary (Genetic) Tylosis

• Gene mutations – Mutations in genes like KRT9 (keratin 9) cause epidermolytic PPK; DSP (desmoplakin) and AQP5 are linked to other inherited forms.
• Inheritance pattern – Most hereditary types are autosomal dominant (50% chance of passing to offspring). X‑linked forms affect males more severely.
• Associated syndromes – Tylosis‑esophageal cancer syndrome (mutation in SPROUTY4) carries a 30–40% lifetime risk of esophageal squamous cell carcinoma.

Acquired Hyperkeratosis

• Chronic friction or pressure – Repeated mechanical stress (e.g., athletes, musicians, manual laborers) triggers hyperkeratinization.
• Dermatologic conditions – Psoriasis, chronic eczema, lichen planus, and Darier disease often show secondary hyperkeratosis.
• Infections – Fungal infections (tinea pedis, tinea manuum) can cause localized hyperkeratotic plaques.
• Environmental exposures – Prolonged contact with chemicals, detergents, or solvents.
• Systemic diseases – Diabetes mellitus, hypothyroidism, and vitamin A deficiency may predispose to thickened skin.
• Medications – Long‑term retinoids, certain chemotherapeutic agents, and B‑complex vitamin excess can induce hyperkeratosis.

Risk Factors

• Family history of PPK or related skin disorders.
• Occupations involving repetitive hand/foot trauma (construction, flooring, gaming).
• Existing skin conditions (psoriasis, eczema).
• Uncontrolled diabetes or thyroid disease.
• Smoking & heavy alcohol use – increase risk of esophageal cancer in tylosis‑esophageal cancer syndrome.

Diagnosis

Diagnosis is primarily clinical but often requires supplemental tests to determine the underlying cause.

History and Physical Examination

• Detailed personal and family skin‑disease history.
• Onset age, pattern of lesions, and aggravating factors (friction, heat, moisture).
• Examination of palms, soles, and any extrapalmar sites for characteristic plaques.

Skin Biopsy

Incisional or punch biopsy of a representative lesion helps differentiate hereditary PPK from acquired forms. Histology typically shows:

• Marked hyperkeratosis (thickened stratum corneum).
• Varying degrees of acanthosis, papillomatosis, and sometimes epidermolysis.

Genetic Testing

Indicated when a hereditary pattern is suspected, especially for:

• Confirming KRT9, DSP, or SPROUTY4 mutations.
• Family counseling and prenatal planning.

Testing is performed via next‑generation sequencing panels for keratinization disorders; results are available within 4–6 weeks (NIH Genetics Home Reference, 2023).

Laboratory Studies (to rule out secondary causes)

• Complete blood count, fasting glucose, HbA1c – evaluate diabetes.
• Thyroid function tests – assess hypothyroidism.
• Serum vitamin A and zinc levels – identify nutritional deficiencies.
• Fungal culture or KOH prep – when a tinea infection is suspected.

Imaging (rare)

In tylosis‑esophageal cancer syndrome, an upper endoscopy is recommended every 2–3 years after age 30 to screen for esophageal neoplasia (CDC, 2022).

Treatment Options

Therapy aims to reduce hyperkeratinization, relieve symptoms, and address any underlying disease. Treatment is individualized based on severity and etiology.

Topical Therapies

• Keratinolytic agents – 12% salicylic acid ointment, 40% urea cream, or 10% lactic acid; applied nightly to soften plaques.
• Topical retinoids – Tazarotene 0.1% or adapalene 0.1% can normalize epidermal turnover; start with 2–3 times weekly to minimize irritation.
• Corticosteroids – Low‑ to mid‑potency steroids (hydrocortisone 2.5% or triamcinolone 0.1%) reduce inflammation in secondary eczema‑associated hyperkeratosis.
• Calcineurin inhibitors – Tacrolimus 0.1% ointment for patients who cannot tolerate steroids.

Systemic Medications

• Oral retinoids – Acitretin (25–50 mg daily) or isotretinoin (0.5 mg/kg) are the mainstay for severe hereditary PPK. Monitor liver function, triglycerides, and pregnancy status.
• Methotrexate or biologics – For hyperkeratosis secondary to psoriasis, methotrexate, apremilast, or TNF‑α inhibitors (etanercept, adalimumab) may be indicated.
• Systemic antifungals – Terbinafine 250 mg daily for 4–6 weeks when a fungal infection is confirmed.

Procedural Interventions

• Mechanical debridement – Gentle filing, pumice stone, or professional keratolysis in a podiatrist’s office.
• Laser therapy – CO₂ or Er:YAG lasers can precisely remove thickened plaques with minimal scarring.
• Phototherapy – Narrow‑band UVB (311 nm) may improve hyperkeratosis associated with psoriasis.
• Surgical excision – Rarely needed, reserved for focal, recalcitrant lesions.

Lifestyle and Self‑Care Measures

• Regular moisturizing with occlusive ointments (petrolatum, glycerin‑based creams) after bathing.
• Use protective gloves or cushioned insoles to reduce friction.
• Keep feet clean and dry; change socks at least twice daily.
• Stay hydrated and maintain a balanced diet rich in vitamins A, C, E, and zinc.
• Quit smoking and limit alcohol if you have tylosis‑esophageal cancer syndrome.

Living with Tylosis (Hyperkeratosis)

Daily Management Tips

• Moisturize strategically – Apply a thick barrier cream immediately after showering while skin is still damp; reapply every 3–4 hours if hands are in frequent use.
• File, don’t cut – Use a fine‑grit foot file or emery board gently to reduce thickness; avoid metal clippers that can cause fissures.
• Footwear choices – Opt for breathable shoes with a wide toe box, soft insoles, and cushioned heels. Rotate pairs to allow drying.
• Hand protection – Wear nitrile or cotton gloves when handling chemicals, gardening, or using tools.
• Regular check‑ups – Schedule dermatology visits every 6–12 months to assess treatment response and screen for secondary infections.
• Psychosocial support – Join patient groups (e.g., National Psoriasis Foundation, Rare Skin Disease Community) for coping strategies and shared experiences.

Monitoring for Complications

Keep a diary of any new pain, color changes, or ulcerations. Early detection of infection or malignant transformation (especially in tylosis‑esophageal syndrome) improves outcomes.

Prevention

• Minimize repetitive trauma – Take regular breaks during activities that stress the palms/soles; use ergonomic tools.
• Maintain skin integrity – Promptly treat cuts, blisters, or fungal infections.
• Control systemic risk factors – Keep diabetes, thyroid disease, and lipid levels within target ranges.
• Genetic counseling – Families with hereditary PPK should consider counseling before planning children.
• Screening for esophageal cancer – For individuals with the tylosis‑esophageal cancer syndrome, undergo surveillance endoscopy as recommended by a gastroenterologist.

Complications

• Secondary infections – Bacterial cellulitis or fungal infections can develop in fissured skin.
• Painful gait or limited hand function – May lead to reduced mobility, work disability, or reduced quality of life.
• Digital ulcers – Deep cracks can bleed and become chronic non‑healing wounds.
• Esophageal squamous cell carcinoma – In tylosis‑esophageal cancer syndrome, the lifetime risk is 30‑40% (American Cancer Society, 2023).
• Psychological impact – Visible lesions, especially on hands, can cause embarrassment, anxiety, or depression.

When to Seek Emergency Care

Sources: Mayo Clinic. “Palmoplantar keratoderma.” 2022; CDC. “Upper gastrointestinal cancers.” 2022; NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases. “Hyperkeratosis.” 2023; WHO. “Skin disorders: factsheet.” 2021; Cleveland Clinic. “Hyperkeratosis treatment options.” 2023; American Cancer Society. “Esophageal cancer statistics.” 2023; peer‑reviewed articles in JAMA Dermatology and British Journal of Dermatology (2020‑2024).